Additional DNA Health Findings
Conditions Beyond issues.txt โ Comprehensive Analysis of 17 Additional Genetic Health Risks
โฐ Summary Overview
This report presents DNA-derived health findings that fall outside the scope of the primary conditions documented in issues.txt. Each section below provides SNP-level genotype data, risk assessments, and evidence-based recommendations.
| # | Category | Overall Risk | Key Finding |
|---|---|---|---|
| 1 | โค๏ธ Cardiovascular | MODERATE | APOE ฮต3/ฮต3 โ baseline risk; ACE TT โ higher ACE activity |
| 2 | ๐ฉธ Blood Clotting | NORMAL | No thrombophilia mutations detected โ |
| 3 | โซ Hemochromatosis | NORMAL | Wild type for HFE C282Y & H63D โ |
| 4 | ๐๏ธ Macular Degeneration | LOW-MODERATE | Heterozygous CFH variants |
| 5 | ๐ฌ Type 2 Diabetes | MODERATE | TCF7L2 CT + CDKAL1 AG variants |
| 6 | ๐ Sleep & Circadian | MILD | MTNR1B CC โ evening preference, melatonin sensitivity |
| 7 | โ๏ธ Vitamin D Status | MILD | DBP AG โ may need higher supplementation |
| 8 | ๐ Omega-3/6 Metabolism | MODERATE | Reduced omega-3 conversion efficiency |
| 9 | ๐ท Alcohol Metabolism | MILD | No clear "flush" mutation detected |
| 10 | ๐ฅ Lactose Intolerance | MILD | AG heterozygous โ partial lactase persistence |
| 11 | โ Caffeine Sensitivity | MODERATE | CYP1A2 AC = intermediate metabolizer |
| 12 | โ๏ธ Weight Management | FAVORABLE | FTO AA = lower obesity risk โ |
| 13 | ๐ฆด Gout / Uric Acid | MODERATE | SLC2A9 CT + TT variants โ higher uric acid |
| 14 | ๐ฏ Cancer Predisposition | LOW | Generally low predisposition |
| 15 | ๐ฆ Thyroid Function | NORMAL | Normal thyroid function expected |
| 16 | ๐ฆด Bone Health | MILD-MODERATE | Moderate consideration; COL1A1 heterozygous |
| 17 | ๐ Blood Pressure | NORMAL | Normal blood pressure genetics |
๐ก Key Takeaway
The most significant findings are in omega-3/6 metabolism, type 2 diabetes risk, and cardiovascular risk markers. Several areas show favorable genetics including weight management, blood clotting, hemochromatosis, thyroid function, and blood pressure. No high-risk variants were identified.
1 โค๏ธ Cardiovascular Disease Risk
APOE & Lipid Metabolism Analysis
Your APOE genotype is ฮต3/ฮต3 โ the most common allele combination. This represents baseline population risk for cardiovascular disease and Alzheimer's disease, neither elevated nor protective.
| SNP | Gene | Genotype | Impact | Risk Level |
|---|---|---|---|---|
| rs429358 | APOE | TT | ฮต3 allele โ baseline | MODERATE |
| rs7412 | APOE | CC | ฮต3 allele โ baseline | MODERATE |
| Derived | APOE | ฮต3/ฮต3 | Moderate (baseline) cardiovascular & Alzheimer's risk | MODERATE |
| rs653178 | ACE | TT | High ACE activity | MODERATE |
| rs7694491 | โ | CT | Variant allele present | MILD |
| rs12740374 | PCSK9 | TT | Variant associated with lipid metabolism | MODERATE |
| rs662 | LPA | CC | Wild type | NORMAL |
Your APOE ฮต3/ฮต3 genotype is neither ฮต4/ฮต4 (which confers high risk for Alzheimer's and cardiovascular disease) nor ฮต2/ฮต2 (which is protective). You have standard population-level risk. The ACE TT genotype indicates higher ACE (angiotensin-converting enzyme) activity, which can contribute to elevated blood pressure and cardiovascular strain over time.
- Heart-healthy diet (Mediterranean-style, low in saturated fats)
- Regular aerobic exercise (150+ minutes/week)
- Monitor cholesterol levels regularly (every 6โ12 months)
- Consider ACE activity biomarkers with your physician
2 ๐ฉธ Blood Clotting / Thrombophilia
Thrombophilia Screening
Thorough screening for the most common inherited blood clotting disorders. All results are normal.
| SNP | Gene | Genotype | Impact | Risk Level |
|---|---|---|---|---|
| rs6025 | Factor V | CC | NOT Factor V Leiden mutation | NORMAL โ |
| rs1799966 | Prothrombin | TT | NOT G20210A mutation | NORMAL โ |
| rs1799967 | Prothrombin | CC | Normal | NORMAL โ |
| rs6046 | โ | GG | Wild type | NORMAL โ |
NO increased clotting risk genetically identified. You do not carry the Factor V Leiden or Prothrombin G20210A mutations, the two most common inherited thrombophilias. Normal clotting profile is reassuring.
3 โซ Hemochromatosis (Iron Overload)
HFE Gene Analysis
Hemochromatosis is an iron overload disorder. Your results show no mutations in the two primary HFE disease-causing variants.
| SNP | Gene | Genotype | Impact | Risk Level |
|---|---|---|---|---|
| rs1800562 | HFE (C282Y) | GG | Wild type โ NOT the mutation | NORMAL โ |
| rs1800563 | HFE (H63D) | GG | Wild type โ NOT the mutation | NORMAL โ |
NO hemochromatosis risk genetically identified. You carry wild-type alleles at both the C282Y and H63D positions. No special iron restrictions are necessary based on genetics alone.
4 ๐๏ธ Macular Degeneration (AMD)
Age-Related Macular Degeneration Risk
Analysis of the most well-established genetic risk variants for age-related macular degeneration (AMD). Multiple heterozygous variants are present, conferring low-moderate increased risk.
| SNP | Gene | Genotype | Impact | Risk Level |
|---|---|---|---|---|
| rs1061170 | CFH | CT | Heterozygous risk variant | LOW-MODERATE |
| rs1410996 | ARMS2 | GG | Normal (protective) | NORMAL โ |
| rs380390 | CFH | CG | Heterozygous variant | LOW-MODERATE |
| rs429608 | โ | AG | Heterozygous variant | LOW-MODERATE |
| rs10490924 | C3 | GG | Normal | NORMAL โ |
LOW-MODERATE AMD risk โ Multiple heterozygous variants in complement pathway genes (CFH) are present. While no single variant carries high risk, the combination elevates lifetime risk above baseline. The ARMS2 GG and C3 GG variants are reassuring.
- Take lutein and zeaxanthin supplements (AREDS2 formula)
- Schedule regular comprehensive eye exams (annually)
- Protect eyes from UV exposure (wear sunglasses)
- Do not smoke โ smoking dramatically increases AMD risk
- Eat dark leafy greens (kale, spinach) regularly
5 ๐ฌ Type 2 Diabetes / Glucose Metabolism
Genetic Risk for Type 2 Diabetes
Multiple variants affecting insulin secretion, insulin sensitivity, and glucose metabolism show risk-associated genotypes. The most significant is the TCF7L2 CT variant, one of the strongest known genetic risk factors for type 2 diabetes.
| SNP | Gene | Genotype | Impact | Risk Level |
|---|---|---|---|---|
| rs7903146 | TCF7L2 | CT | Moderate increased risk โ impairs insulin secretion | MODERATE |
| rs1801282 | KCNJ11 | CC | Normal | NORMAL โ |
| rs1801274 | KCNJ11 | AG | Slight concern โ beta cell function | MILD |
| rs7756992 | CDKAL1 | AG | Moderate risk โ insulin secretion | MODERATE |
| rs10830962 | MTNR1B | GG | Higher fasting glucose | MODERATE |
| rs10830963 | MTNR1B | CC | Impaired melatonin-glucose interaction | MODERATE |
| rs17817449 | โ | GG | Wild type | NORMAL โ |
MODERATE genetic risk for type 2 diabetes. The TCF7L2 CT variant is the strongest individual risk factor identified. Combined with CDKAL1 AG and MTNR1B GG/CC variants, your genetic profile suggests reduced capacity for optimal glucose handling. Lifestyle intervention can significantly mitigate this risk.
- Monitor blood sugar (fasting glucose, HbA1c) annually
- Follow a low-glycemic index diet
- Regular exercise (both aerobic and resistance training)
- Maintain healthy body weight
- Consider magnesium supplementation (supports glucose metabolism)
- Limit refined carbohydrates and added sugars
6 ๐ Sleep & Circadian Rhythm
Sleep Timing & Melatonin Sensitivity
Genetic variants related to your circadian rhythm and melatonin signaling suggest an evening chronotype with potential sensitivity to melatonin fluctuations.
| SNP | Gene | Genotype | Impact | Risk Level |
|---|---|---|---|---|
| rs10830963 | MTNR1B | CC | Evening preference, potential melatonin sensitivity | MILD |
| rs2070045 | PER2 | TT | Normal circadian rhythm | NORMAL โ |
| rs737866 | CRY1 | CC | May affect sleep timing | MILD |
Your MTNR1B CC genotype is associated with a natural evening preference ("night owl" tendency) and increased sensitivity to melatonin. The CRY1 CC variant may shift your sleep timing later. However, PER2 TT is normal, suggesting your core circadian clock function is intact.
- Maintain a consistent sleep schedule (even on weekends)
- Get morning sunlight exposure within 1 hour of waking
- Avoid bright screens 2 hours before bed
- Consider low-dose melatonin (0.5โ3 mg) if sleep-onset is difficult
- Keep bedroom cool and dark
7 โ๏ธ Vitamin D Status
Vitamin D Receptor & Binding Protein Analysis
Vitamin D metabolism involves both receptor function (VDR) and transport via the vitamin D-binding protein (DBP). Your genotype suggests you may need higher vitamin D supplementation to achieve optimal blood levels.
| SNP | Gene | Genotype | Impact | Risk Level |
|---|---|---|---|---|
| rs1544410 | VDR (BsmI) | CC | Normal vitamin D receptor | NORMAL โ |
| rs2228570 | VDR (FokI) | GG | Normal | NORMAL โ |
| rs4588 | DBP | AG | May affect vitamin D transport efficiency | MILD |
| rs11568820 | VDR (TaqI) | CC | Normal | NORMAL โ |
| rs7754530 | GC | TT | Variant affecting vitamin D binding protein | MILD |
While your VDR genotypes are normal, the DBP AG variant (rs4588) may reduce the efficiency of vitamin D transport in the blood, meaning you might need higher doses to achieve the same blood levels as someone with a non-carrier genotype.
- Monitor 25-OH-Vitamin D levels regularly (target: 30โ60 ng/mL)
- Consider higher supplementation dose than standard (1000โ4000 IU/day)
- Take vitamin D3 with fat (K2 may enhance absorption)
- Get sensible sun exposure when possible
- Recheck levels after 3 months of supplementation
8 ๐ Omega-3/6 Fatty Acid Metabolism
FADS1/FADS2 Conversion Efficiency
The FADS gene cluster encodes enzymes critical for converting plant-based omega-3 fatty acids (ALA from flax, chia, walnuts) into the active forms EPA and DHA. Your genotype indicates reduced conversion efficiency.
| SNP | Gene | Genotype | Impact | Risk Level |
|---|---|---|---|---|
| rs174546 | FADS1 | CC | Reduced omega-3 conversion efficiency | MODERATE |
| rs174547 | FADS2 | TT | Reduced omega-3 conversion | MODERATE |
| rs174575 | FADS1 | CC | Reduced conversion efficiency | MODERATE |
REDUCED ABILITY TO CONVERT PLANT OMEGA-3s TO EPA/DHA. This means that relying on flaxseed, chia seeds, walnuts, or canola oil alone will not provide adequate EPA/DHA. You need direct sources of pre-formed omega-3 fatty acids.
- Take direct EPA/DHA supplementation (fish oil or algae-based)
- Aim for 1โ2 g/day combined EPA+DHA
- Eat fatty fish 2โ3 times per week (salmon, sardines, mackerel)
- Don't rely on flax/chia alone for omega-3 needs
- Reduce excessive omega-6 intake (processed vegetable oils)
- Maintain a balanced omega-6:omega-3 ratio (~4:1 or lower)
9 ๐ท Alcohol Metabolism
Alcohol Dehydrogenase / Aldehyde Dehydrogenase
Analysis of alcohol metabolism pathway genes. No clear "alcohol flush" mutation was detected on this genetic array, but some variants were noted in related pathways.
| SNP | Gene | Genotype | Impact | Risk Level |
|---|---|---|---|---|
| rs6712 | ALDH2 | CT | Variant detected (not classic "flush" genotype) | MILD |
| Related variants | ADH family | CT/AG | Multiple variants in alcohol metabolism family | MILD |
The classic "Asian flush" reaction is caused by the ALDH2 rs6712 AA genotype (complete enzyme deficiency). Your CT genotype is not the full "flush" mutation, but variants were found across the alcohol dehydrogenase family. This suggests moderate alcohol metabolism capacity.
- Moderate alcohol consumption (if consumed at all)
- Monitor liver function tests periodically
- Avoid binge drinking
- Ensure adequate hydration when consuming alcohol
10 ๐ฅ Lactose Intolerance
Lactase Persistence Analysis
The ability to digest lactose (milk sugar) into adulthood is determined by the LCT/MCM6 gene region. Your genotype shows partial lactase persistence.
| SNP | Gene | Genotype | Impact | Risk Level |
|---|---|---|---|---|
| rs4988235 | MCM6/LCT | AG | Heterozygous โ partial lactase persistence | MILD |
AG = HETEROZYGOUS for partial lactase persistence. This typically means you can tolerate dairy in moderation but may experience symptoms (bloating, gas, discomfort) with large amounts of lactose-containing foods. The phenotype can vary โ some AG individuals tolerate dairy well, while others are mildly sensitive.
- Monitor your personal dairy tolerance
- Consider lactase enzyme supplements if symptomatic
- Opt for aged cheeses and yogurt (naturally lower lactose)
- Use lactose-free milk if needed
- Ensure calcium and vitamin D intake through other sources
11 โ Caffeine Sensitivity
Caffeine Metabolism & Adenosine Receptor
Caffeine sensitivity is influenced by both how quickly you metabolize caffeine (CYP1A2) and your brain's response to adenosine (ADORA2A). Your profile shows intermediate caffeine metabolism.
| SNP | Gene | Genotype | Impact | Risk Level |
|---|---|---|---|---|
| rs5751876 | ADORA2A | CC | Normal adenosine receptor | NORMAL โ |
| rs762551 | CYP1A2 | AC | Intermediate metabolizer (see detailed.md) | MODERATE |
Your CYP1A2 AC genotype means you metabolize caffeine at an intermediate rate โ slower than "fast metabolizers" but faster than "slow metabolizers." You also have a normal ADORA2A genotype, meaning you are unlikely to experience caffeine-induced anxiety or jitteriness from adenosine receptor sensitivity. The main concern is caffeine lingering in your system longer.
- Limit caffeine to 1โ2 cups per day
- Avoid caffeine after noon (intermediate clearance)
- Watch for sleep disruption from afternoon coffee
- Consider switching to decaf in the afternoon
- Note: Full caffeine analysis is in detailed.html
12 โ๏ธ Weight Management
Genetic Profile for Weight Management
Analysis of genes involved in appetite regulation, energy balance, and obesity susceptibility. The results are genetically favorable for weight management.
| SNP | Gene | Genotype | Impact | Risk Level |
|---|---|---|---|---|
| rs9939609 | FTO | AA | Lower obesity risk | FAVORABLE โ |
| rs17782313 | MC4R | CT | Slight increased appetite | MILD |
| rs12970134 | โ | AG | Variant allele present | MILD |
| rs1558902 | FTO | AA | Lower obesity risk | FAVORABLE โ |
๐ Favorable Genetics for Weight Control
Both FTO variants (rs9939609 AA and rs1558902 AA) are associated with lower genetic risk for obesity. The FTO gene is one of the strongest known genetic factors for body weight. While MC4R CT may slightly increase appetite, your overall profile is genetically favorable for weight management. Genetics support good weight control potential.
- Maintain a healthy lifestyle โ your genetics are on your side!
- Regular physical activity and balanced nutrition
- Be mindful of appetite (MC4R CT โ slight increase)
- Use your genetic advantage as motivation
13 ๐ฆด Gout / Uric Acid
Uric Acid Excretion & Gout Risk
The SLC2A9 gene encodes a renal uric acid transporter. Variants in this gene are among the strongest known genetic risk factors for elevated serum uric acid levels and gout.
| SNP | Gene | Genotype | Impact | Risk Level |
|---|---|---|---|---|
| rs780094 | SLC2A9 | CT | Moderate risk for higher uric acid | MODERATE |
| rs1800684 | SLC2A9 | TT | Increased risk for elevated uric acid | MODERATE |
MODERATE GOUT RISK. Two SLC2A9 variants both point toward reduced renal uric acid excretion, leading to higher baseline serum uric acid levels. This increases the risk of gout attacks and kidney stones over time.
- Limit purine-rich foods (red meat, organ meats, shellfish)
- Stay well-hydrated (2โ3 liters of water daily)
- Limit alcohol, especially beer (increases uric acid)
- Monitor serum uric acid levels periodically
- Limit fructose-sweetened beverages
- Cherries and tart cherry juice may help lower uric acid
14 ๐ฏ Cancer Predisposition
Cancer-Related Genetic Variants
Comprehensive screening of genetic variants associated with increased cancer susceptibility. Overall, genetic cancer predisposition appears generally low, though some variants warrant awareness.
| SNP | Gene | Genotype | Impact | Risk Level |
|---|---|---|---|---|
| rs1801131 | MTHFR A1298C | TT | Mild concern โ methylation | MILD |
| rs1801132 | MTHFR A1298C | CC | Normal | NORMAL โ |
| rs2853669 | BRCA1 promoter | AG | Variant (not a BRCA mutation, promoter variant) | MILD |
| rs6887695 | BRCA1 | GG | Normal | NORMAL โ |
| rs1800627 | APC | AA | Normal | NORMAL โ |
| rs1800629 | MTHFR | GG | Normal | NORMAL โ |
| rs6983267 | MYC enhancer | GT | Slight colon cancer risk increase | MILD |
| rs6983561 | MYC enhancer | AA | Normal | NORMAL โ |
| rs2294008 | TERT | CC | Normal | NORMAL โ |
| rs11540652 | p53 | CC | Normal | NORMAL โ |
| rs1042522 | p53 | CC | Normal | NORMAL โ |
| rs4939827 | CDKN2B-AS1 | CT | Variant | MILD |
| rs7903146 | TCF7L2 | CT | Diesel risk (see section 5) | MODERATE |
Generally low cancer predisposition. The most notable findings are the MTHFR A1298C TT variant (affecting methylation) and the MYC enhancer GT variant (slight colon cancer risk increase). Importantly, no pathogenic BRCA mutations were detected โ the BRCA1 promoter variant is not a cancer-causing mutation. The rs2853669 AG variant is a promoter region variant, not a coding mutation.
- Maintain standard cancer screening guidelines for your age
- Consider earlier colonoscopy (MYC enhancer variant)
- Support methylation (B vitamins, folate โ see MTHFR section)
- Healthy diet rich in cruciferous vegetables (sulforaphane)
- Regular exercise and maintain healthy body weight
- Do not smoke
15 ๐ฆ Thyroid Function
Thyroid Receptor Genotype
Analysis of the TSH receptor (TSHR) gene, which mediates thyroid-stimulating hormone action. Your genotype suggests normal thyroid function.
| SNP | Gene | Genotype | Impact | Risk Level |
|---|---|---|---|---|
| rs2235544 | TSHR | AA | Normal TSH receptor | NORMAL โ |
| rs965513 | TSHR | AG | Heterozygous variant | MILD |
Normal thyroid function expected. The AA genotype at rs2235544 is the most common and is associated with normal TSH receptor function. The heterozygous AG at rs965513 is a common variant that, on its own, is not associated with clinical thyroid disease.
- Monitor TSH if symptoms of thyroid dysfunction develop
- Annual thyroid screening as part of routine physicals
16 ๐ฆด Bone Health / Osteoporosis
Bone Density & Structure Genes
Analysis of genes involved in bone mineral density, collagen structure, and calcium regulation. Your profile suggests moderate bone health consideration needed.
| SNP | Gene | Genotype | Impact | Risk Level |
|---|---|---|---|---|
| rs1544410 | VDR (BsmI) | CC | Normal vitamin D receptor for bone health | NORMAL โ |
| rs4516035 | VDR | CC | Normal VDR variant | NORMAL โ |
| rs7754530 | GC | TT | Variant in vitamin D-binding protein | MILD |
| rs2073618 | VDR | CG | Heterozygous VDR variant | MILD |
| rs4778893 | COL1A1 | AG | Heterozygous โ collagen type I variant | MODERATE |
MODERATE bone health consideration. While your VDR genotypes are generally favorable for bone health, the COL1A1 AG variant is associated with slightly lower bone mineral density. Combined with the GC TT variant (affecting vitamin D transport), proactive bone health measures are recommended.
- Ensure adequate calcium intake (1000โ1200 mg/day)
- Maintain optimal vitamin D levels (see section 7)
- Weight-bearing exercise (walking, resistance training)
- Adequate protein intake for bone matrix
- Consider bone density scan (DEXA) at appropriate age
- Avoid smoking and limit alcohol
17 ๐ Blood Pressure
Blood Pressure Genetic Risk Assessment
Analysis of genes involved in blood pressure regulation, including the renin-angiotensin system (AGT, ADD1). Your results show normal blood pressure genetics.
| SNP | Gene | Genotype | Impact | Risk Level |
|---|---|---|---|---|
| rs1042522 | p53 | CC | Normal | NORMAL โ |
| rs11540652 | p53 | CC | Normal | NORMAL โ |
| rs683240 | AGT | AA | Normal angiotensinogen | NORMAL โ |
| rs1800566 | ADD1 | GG | Normal adducin | NORMAL โ |
Normal blood pressure genetics. All analyzed variants associated with blood pressure regulation are wild-type/normal. This is reassuring, especially in combination with your favorable weight management genetics. Maintain your healthy lifestyle to continue protecting cardiovascular health.
- Maintain healthy lifestyle (your genetics support this)
- Monitor blood pressure during routine checkups
- Limit sodium intake (general recommendation)
- Regular physical activity
- Manage stress effectively
โ๏ธ Medical Disclaimer
- This report is based on analysis of 23andMe raw genotype data and is for informational and educational purposes only. It is not a medical diagnosis or substitute for professional medical advice.
- Genetic risk assessments reflect predisposition only โ they do not predict whether you will develop any condition. Environmental factors, lifestyle, and chance play major roles in health outcomes.
- Always consult with a qualified healthcare provider before making changes to your diet, supplementation, exercise, or medication regimen.
- Genetic testing should be interpreted in the context of your complete medical history, family history, and clinical laboratory results.
- Some findings are based on research associations that may not be clinically validated. Effect sizes for individual SNPs are typically modest.
- This analysis covers only the genetic variants present on the 23andMe genotyping array. Comprehensive genomic sequencing may reveal additional relevant variants.